Search Results - "SHAH, Bijal"

Executive (agency) administration by Shah, Bijal

“…The current account of executive power is incomplete. Before joining the Supreme Court, Elena Kagan noted that the President seeks control over the executive…”
Get full text

UNCOVERING COORDINATED INTERAGENCY ADJUDICATION by Shah, Bijal

“…Administrative adjudication often involves interagency coordination. This Article establishes that this phenomenon, which it terms "coordinated interagency…”
Get full text

Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma by Logue, Jennifer M, Zucchetti, Elisa, Bachmeier, Christina A, Krivenko, Gabriel S, Larson, Victoria, Ninh, Daniel, Grillo, Giovanni, Cao, Biwei, Kim, Jongphil, Chavez, Julio C, Baluch, Aliyah, Khimani, Farhad, Lazaryan, Aleksandr, Nishihori, Taiga, Liu, Hien D, Pinilla-Ibarz, Javier, Shah, Bijal D, Faramand, Rawan, Coghill, Anna E, Davila, Marco L, Dholaria, Bhagirathbhai R, Jain, Michael D, Locke, Frederick L

“…CD19 CAR T-cell therapy with axicabtagene ciloleucel (axi-cel) for relapsed or refractory (R/R) large B cell lymphoma (LBCL) may lead to durable remissions,…”
Get full text

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study by Shah, Bijal D, Ghobadi, Armin, Oluwole, Olalekan O, Logan, Aaron C, Boissel, Nicolas, Cassaday, Ryan D, Leguay, Thibaut, Bishop, Michael R, Topp, Max S, Tzachanis, Dimitrios, O'Dwyer, Kristen M, Arellano, Martha L, Lin, Yi, Baer, Maria R, Schiller, Gary J, Park, Jae H, Subklewe, Marion, Abedi, Mehrdad, Minnema, Monique C, Wierda, William G, DeAngelo, Daniel J, Stiff, Patrick, Jeyakumar, Deepa, Feng, Chaoling, Dong, Jinghui, Shen, Tong, Milletti, Francesca, Rossi, John M, Vezan, Remus, Masouleh, Behzad Kharabi, Houot, Roch

“…Despite treatment with novel therapies and allogeneic stem-cell transplant (allo-SCT) consolidation, outcomes in adult patients with relapsed or refractory…”
Get full text

Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T) by Alvi, Raza M., Frigault, Matthew J., Fradley, Michael G., Jain, Michael D., Mahmood, Syed S., Awadalla, Magid, Lee, Dae Hyun, Zlotoff, Daniel A., Zhang, Lili, Drobni, Zsofia D., Hassan, Malek Z.O., Bassily, Emmanuel, Rhea, Isaac, Ismail-Khan, Roohi, Mulligan, Connor P., Banerji, Dahlia, Lazaryan, Aleksandr, Shah, Bijal D., Rokicki, Adam, Raje, Noopur, Chavez, Julio C., Abramson, Jeremy, Locke, Frederick L., Neilan, Tomas G.

“…Chimeric antigen receptors redirect T cells (CAR-T) to target cancer cells. There are limited data characterizing cardiac toxicity and cardiovascular (CV)…”
Get full text

Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma by Sim, Austin J., Jain, Michael D., Figura, Nicholas B., Chavez, Julio C., Shah, Bijal D., Khimani, Farhad, Lazaryan, Aleksandr, Krivenko, Gabriel, Davila, Marco L., Liu, Hien D., Falchook, Aaron D., Dahiya, Saurabh, Rapoport, Aaron P., Kim, Sungjune, Locke, Frederick L., Robinson, Timothy J.

“…Axicabtagene ciloleucel (axi-cel) is a CD19-directed chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma…”
Get full text

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial by Wang, Michael, Rule, Simon, Zinzani, Pier Luigi, Goy, Andre, Casasnovas, Olivier, Smith, Stephen D, Damaj, Gandhi, Doorduijn, Jeanette, Lamy, Thierry, Morschhauser, Franck, Panizo, Carlos, Shah, Bijal, Davies, Andrew, Eek, Richard, Dupuis, Jehan, Jacobsen, Eric, Kater, Arnon P, Le Gouill, Steven, Oberic, Lucie, Robak, Taduesz, Covey, Todd, Dua, Richa, Hamdy, Ahmed, Huang, Xin, Izumi, Raquel, Patel, Priti, Rothbaum, Wayne, Slatter, J Greg, Jurczak, Wojciech

“…Bruton tyrosine kinase is a clinically validated target in mantle cell lymphoma. Acalabrutinib (ACP-196) is a highly selective, potent Bruton tyrosine kinase…”
Get full text

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma by Ruan, Jia, Martin, Peter, Shah, Bijal, Schuster, Stephen J, Smith, Sonali M, Furman, Richard R, Christos, Paul, Rodriguez, Amelyn, Svoboda, Jakub, Lewis, Jessica, Katz, Orel, Coleman, Morton, Leonard, John P

“…Mantle-cell lymphoma is usually treated with intensive chemotherapy. In this study of lenalidomide plus rituximab as initial therapy for mantle-cell lymphoma,…”
Get full text

Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study by Shah, Bijal D, Ghobadi, Armin, Oluwole, Olalekan O, Logan, Aaron C, Boissel, Nicolas, Cassaday, Ryan D, Leguay, Thibaut, Bishop, Michael R, Topp, Max S, Tzachanis, Dimitrios, O'Dwyer, Kristen M, Arellano, Martha L, Lin, Yi, Baer, Maria R, Schiller, Gary J, Park, Jae H, Subklewe, Marion, Abedi, Mehrdad, Minnema, Monique C, Wierda, William G, DeAngelo, Daniel J, Stiff, Patrick, Jeyakumar, Deepa, Dong, Jinghui, Adhikary, Sabina, Zhou, Lang, Schuberth, Petra C, Faghmous, Imi, Masouleh, Behzad Kharabi, Houot, Roch

“…Brexucabtagene autoleucel (KTE-X19) is an autologous anti-CD19 CAR T-cell therapy approved in the USA to treat adult patients with relapsed or refractory…”
Get full text

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results by Shah, Bijal D., Bishop, Michael R., Oluwole, Olalekan O., Logan, Aaron C., Baer, Maria R., Donnellan, William B., O'Dwyer, Kristen M., Holmes, Houston, Arellano, Martha L., Ghobadi, Armin, Pagel, John M., Lin, Yi, Cassaday, Ryan D., Park, Jae H., Abedi, Mehrdad, Castro, Januario E., DeAngelo, Daniel J., Malone, Adriana K., Mawad, Raya, Schiller, Gary J., Rossi, John M., Bot, Adrian, Shen, Tong, Goyal, Lovely, Jain, Rajul K., Vezan, Remus, Wierda, William G.

“…ZUMA-3 is a phase 1/2 study evaluating KTE-X19, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult relapsed/refractory (R/R)…”
Get full text

Dose fractionation of CAR-T cells. A systematic review of clinical outcomes by Frigault, Matthew, Rotte, Anand, Ansari, Ayub, Gliner, Bradford, Heery, Christopher, Shah, Bijal

“…CAR-T cells are widely recognized for their potential to successfully treat hematologic cancers and provide durable response. However, severe adverse events…”
Get full text

Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy by Figura, Nicholas B., Robinson, Timothy J., Sim, Austin J., Wang, Xuefeng, Cao, Biwei, Chavez, Julio C., Shah, Bijal D., Khimani, Farhad, Lazaryan, Aleksandr, Davila, Marco, Bachmeier, Christina, Nishihori, Taiga, Liu, Hien D., Kim, Sungjune, Locke, Frederick L., Jain, Michael D.

“…Chimeric antigen receptor T-cell (CAR T) therapy is capable of eliciting durable responses in patients with relapsed/refractory (R/R) lymphomas. However, most…”
Get full text

Protein aggregation can inhibit clathrin-mediated endocytosis by chaperone competition by Yu, Anan, Shibata, Yoko, Shah, Bijal, Calamini, Barbara, Lo, Donald C, Morimoto, Richard I

“…Protein conformational diseases exhibit complex pathologies linked to numerous molecular defects. Aggregation of a disease-associated protein causes the…”
Get full text

Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma by Ruan, Jia, Martin, Peter, Christos, Paul, Cerchietti, Leandro, Tam, Wayne, Shah, Bijal, Schuster, Stephen J., Rodriguez, Amelyn, Hyman, David, Calvo-Vidal, Maria Nieves, Smith, Sonali M., Svoboda, Jakub, Furman, Richard R., Coleman, Morton, Leonard, John P.

“…We report 5-year follow-up of a multicenter phase 2 study of lenalidomide plus rituximab (LR) as initial treatment of mantle cell lymphoma (MCL). The regimen…”
Get full text

BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models by Zhao, Xiaohong, Ren, Yuan, Lawlor, Matthew, Shah, Bijal D., Park, Paul M.C., Lwin, Tint, Wang, Xuefeng, Liu, Kenian, Wang, Michelle, Gao, Jing, Li, Tao, Xu, Mousheng, Silva, Ariosto S., Lee, Kaplan, Zhang, Tinghu, Koomen, John M., Jiang, Huijuan, Sudalagunta, Praneeth R., Meads, Mark B., Cheng, Fengdong, Bi, Chengfeng, Fu, Kai, Fan, Huitao, Dalton, William S., Moscinski, Lynn C., Shain, Kenneth H., Sotomayor, Eduardo M., Wang, Gang Greg, Gray, Nathanael S., Cleveland, John L., Qi, Jun, Tao, Jianguo

“…Drug-tolerant “persister” tumor cells underlie emergence of drug-resistant clones and contribute to relapse and disease progression. Here we report that…”
Get full text

High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma by Dean, Erin A., Mhaskar, Rahul S., Lu, Hong, Mousa, Mina S., Krivenko, Gabriel S., Lazaryan, Aleksandr, Bachmeier, Christina A., Chavez, Julio C., Nishihori, Taiga, Davila, Marco L., Khimani, Farhad, Liu, Hien D., Pinilla-Ibarz, Javier, Shah, Bijal D., Jain, Michael D., Balagurunathan, Yoganand, Locke, Frederick L.

“…High metabolic tumor volume (MTV) predicts worse outcomes in lymphoma treated with chemotherapy. However, it is unknown if this holds for patients treated with…”
Get full text

Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function by Watters, January M., Wright, Gabriela, Smith, Matthew A., Shah, Bijal, Wright, Kenneth L.

“…Mantle Cell Lymphoma (MCL) is a non-Hodgkin lymphoma with a median survival rate of five years. Standard treatment with high-dose chemotherapy plus rituximab…”
Get full text

PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas by Ren, Yuan, Bi, Chengfeng, Zhao, Xiaohong, Lwin, Tint, Wang, Cheng, Yuan, Ji, Silva, Ariosto S, Shah, Bijal D, Fang, Bin, Li, Tao, Koomen, John M, Jiang, Huijuan, Chavez, Julio C, Pham, Lan V, Sudalagunta, Praneeth R, Wan, Lixin, Wang, Xuefeng, Dalton, William S, Moscinski, Lynn C, Shain, Kenneth H, Vose, Julie, Cleveland, John L, Sotomayor, Eduardo M, Fu, Kai, Tao, Jianguo

“…Concordant activation of MYC and BCL-2 oncoproteins in double-hit lymphoma (DHL) results in aggressive disease that is refractory to treatment. By integrating…”
Get full text

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma by Zhao, Xiaohong, Lwin, Tint, Silva, Ariosto, Shah, Bijal, Tao, Jiangchuan, Fang, Bin, Zhang, Liang, Fu, Kai, Bi, Chengfeng, Li, Jiannong, Jiang, Huijuan, Meads, Mark B., Jacobson, Timothy, Silva, Maria, Distler, Allison, Darville, Lancia, Zhang, Ling, Han, Ying, Rebatchouk, Dmitri, Di Liberto, Maurizio, Moscinski, Lynn C., Koomen, John M., Dalton, William S., Shain, Kenneth H., Wang, Michael, Sotomayor, Eduardo, Tao, Jianguo

“…The novel Bruton’s tyrosine kinase inhibitor ibrutinib has demonstrated high response rates in B-cell lymphomas; however, a growing number of ibrutinib-treated…”
Get full text

Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors by Le Gouill, Steven, Długosz-Danecka, Monika, Rule, Simon, Zinzani, Pier Luigi, Goy, Andre, Smith, Stephen D, Doorduijn, Jeanette K, Panizo, Carlos, Shah, Bijal D, Davies, Andrew J, Eek, Richard, Jacobsen, Eric, Kater, Arnon P, Robak, Tadeusz, Jain, Preetesh, Calvo, Roser, Tao, Lin, Wang, Michael

Get full text